Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 16:29:18 GMT 2025
by
admin
on
Tue Apr 01 16:29:18 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
13U1W2G8EZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
13U1W2G8EZ
Created by
admin on Tue Apr 01 16:29:18 GMT 2025 , Edited by admin on Tue Apr 01 16:29:18 GMT 2025
|
PRIMARY | |||
|
P29320
Created by
admin on Tue Apr 01 16:29:18 GMT 2025 , Edited by admin on Tue Apr 01 16:29:18 GMT 2025
|
PRIMARY | |||
|
EC 2.7.10.1
Created by
admin on Tue Apr 01 16:29:18 GMT 2025 , Edited by admin on Tue Apr 01 16:29:18 GMT 2025
|
PRIMARY | |||
|
EPH RECEPTOR A3
Created by
admin on Tue Apr 01 16:29:18 GMT 2025 , Edited by admin on Tue Apr 01 16:29:18 GMT 2025
|
PRIMARY | |||
|
P29320
Created by
admin on Tue Apr 01 16:29:18 GMT 2025 , Edited by admin on Tue Apr 01 16:29:18 GMT 2025
|
PRIMARY |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_212 |
| N | 1_317 |
| N | 1_371 |
| N | 1_384 |
| N | 1_473 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
WEAK INHIBITOR->TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
LIGAND->TARGET |
EphA3 is an oncofetal antigen with restricted tissue expression, the development of a targeted agent holds promise. Four mechanisms of cell killing have been described: direct induction of apoptosis, activation of antibody-dependent cell-mediated cytotoxicity (ADCC), disruption of tumor vasculature and inhibition of survival signaling from the marrow microenvironment.
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
Structural Modifications
| Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
|---|---|---|---|---|---|---|
| AMINO ACID SUBSTITUTION | [1_917] | TYROSINE | TYROSINE O-PHOSPHATE | 2R86C98KDX | ||
| AMINO ACID SUBSTITUTION | [1_576] [1_582] [1_681] [1_759] | TYROSINE | TYROSINE O-PHOSPHATE | 2R86C98KDX |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER AVERAGE(CALCULATED) | CHEMICAL |
|